Atrial Fibrillation
A stroke occurs when the blood supply to part of the brain is interrupted. Patients with an irregular heart beat (known as atrial fibrillation) are at increased risk of stroke. Preventing stroke in these patients is a key focus of our cardiovascular team. Boehringer Ingelheim developed the first non-vitamin K antagonist oral anticoagulant (NOAC) to protect patients with non-valvular atrial fibrillation against stroke, advancing anticoagulation care.
Latest Articles
Artrial Fibrillation
How do I treat mild to moderate renal impairment with Pradaxa®
Artrial Fibrillation
Professor Gregory Lip introduces the GLORIA™-AF Registry
Artrial Fibrillation
Stroke Prevention in AF
Click here for more information on Stroke Prevention in Atrial Fibrillation